Abstract | PURPOSE: METHODS AND MATERIALS: High-risk M0 prostate cancer patients ( prostate-specific antigen>20 ng/mL, Gleason score>7, or>T3) were eligible for this prospective trial of dose-escalated radioactive 153Sm-EDTMP (.25-2.0 mCi/kg) as primary or postoperative therapy. After 1 month of HT, we administered 153Sm-EDTMP followed by 4 more months of HT, 46.8 Gy to the pelvic region and 23.4 Gy to the prostate target (TD=70.2 Gy). The primary endpoint was Grade III toxicity or higher by the National Cancer Institute Common Toxicity Criteria. RESULTS: Twenty-nine patients enrolled (median prostate-specific antigen=8.2 ng/mL, 27/29 (93%) T stage≥T2b, 24/29 (83%) had Gleason>7) and received 153Sm-EDTMP (.25 mCi/kg, 4 patients; 0.5 mCi/kg, 4 patients; 0.75 mCi/kg, 6 patients; 1.0 mCi/kg, 6 patients; 1.5 mCi/kg, 5 patients; 2.0 mCi/kg, 4 patients). Twenty-eight patients underwent all planned therapy without delays (1 patient required surgery before the start of RT). With a median follow-up time of 23 months, there were 2 patients (7%) experiencing Grade III hematologic toxicity. There were no other Grade III or IV side effects. CONCLUSIONS: Our trial demonstrates that 2 mCi/kg 153Sm -EDTMP with HT and RT was safe and feasible in men with high-risk M0 prostate cancer. A Phase II study to test this treatment is currently underway by the Radiation Therapy Oncology Group.
|
Authors | Richard K Valicenti, Edouard Trabulsi, Charles Intenzo, Jorosali Lavarino, Yihuan Xu, Inna Chervoneva |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 79
Issue 3
Pg. 732-7
(Mar 01 2011)
ISSN: 1879-355X [Electronic] United States |
PMID | 20399029
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Published by Elsevier Inc. |
Chemical References |
- Organometallic Compounds
- Organophosphorus Compounds
- samarium Sm-153 lexidronam
- Prostate-Specific Antigen
|
Topics |
- Aged
- Aged, 80 and over
- Combined Modality Therapy
(methods)
- Feasibility Studies
- Humans
- Leukopenia
(chemically induced)
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Organometallic Compounds
(administration & dosage, adverse effects)
- Organophosphorus Compounds
(administration & dosage, adverse effects)
- Prospective Studies
- Prostate-Specific Antigen
(blood)
- Prostatectomy
- Prostatic Neoplasms
(blood, drug therapy, pathology, radiotherapy, surgery)
- Radiotherapy Dosage
- Thrombocytopenia
(chemically induced)
|